Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial).

See ANZCTR for full trial details >

 

Trial summary:

ACTICCA-1 is a clinical research study for people who have a cancer of the biliary tract (cancer of the gall bladder or bile duct, also known as cholangiocarcinoma) which has been removed in an operation. It is hoped that the findings of this study will provide details on whether giving cisplatin and gemcitabine chemotherapy following surgery for cancer of the biliary tract is a safe and effective treatment to reduce the chance of disease progression and increase survival time and quality of life.

Supported By:

Led by the University Medical Centre Hamburg- Eppendorf in Germany and conducted in Australia by the Australasian Gastro-Intestinal Trials Group (AGITG) in collaboration with the National Health and Medical Research Centre Clinical Trials Centre (NHMRC CTC), University of Sydney.

Eligibility:

Consenting male and female patients over the age of 18 with completely resected cancer of the biliary tract

Objectives:

40 patients from 12 ANZ sites

Registration ID:

ACTRN12615001283561

Participation:

Australia

Australian Lead Group:

NHMRC Clinical Trials Centre 

Status:

Closed

Activation Date:

25/07/2016

Chairs:

Dr Jenny Shannon

Contact:

acticca1.study@sydney.edu.au